Allogeneic stem cell therapy

Unassigned

New Medicines

Multistem · Treatment of ischaemic stroke

Information

Multistem
Advanced therapy medicinal product (ATMP)
Athersys
Athersys

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Adult stem cell product, manufactured from human stem cells obtained from adult bone marrow or other non-embryonic tissue sources, and then significantly expanded in a controlled manner (e.g. from a single qualified donor to produce millions of doses)
There are more than 100,000 strokes in the UK each year. The rate of first-time strokes in people aged 45 and over is expected to increase by 59% in the next 20 years (to 2035). In the same period, it is estimated that the number of stroke survivors, aged 45 and over, living in the UK is expected to rise by 123% [1].
Treatment of ischaemic stroke
Intravenous infusion